Muscarinic acetylcholine receptors (mAChRs) have long been viewed as viable targets for novel therapeutic agents for the treatment of Alzheimer's disease and other disorders involving impaired cognitive function. In an attempt to identify orthosteric and allosteric modulators of the muscarinic acetylcholine receptor M 4 (M 4 ), we developed a homogenous, multiparametric, 1536-well assay to measure M 4 receptor agonism, positive allosteric modulation (PAM), and antagonism in a single well. This assay yielded a Z′ of 0.85 ± 0.05 in the agonist, 0.72 ± 0.07 in PAM, and 0.80 ± 0.06 in the antagonist mode. Parallel screening of the M 1 and M 5 subtypes using the same multiparametric assay format revealed chemotypes that demonstrate selectivity and/or promiscuity between assays and modalities. This identified 503 M 4 selective primary agonists, 1450 PAMs, and 2389 antagonist hits. Concentration-response analysis identified 25 selective agonists, 4 PAMs, and 41 antagonists. This demonstrates the advantages of this approach to rapidly identify selective receptor modulators while efficiently removing assay artifacts and undesirable compounds.
Introduction
G-protein-coupled receptors (GPCRs) are implicated in a multitude of human disorders that have been linked to associated mutations and polymorphisms. 1, 2 These receptors are encoded by more than 1000 genes, yet synthetic ligands exist for only a small fraction of the receptor superfamily. 3 Another approach to discovering ligands that act on the orthosteric site of GPCRs is the development of selective modulators that bind at an alternatively located binding site (allosteric site) to either potentiate or inhibit the activation of the receptor by its natural ligand. 4 This approach has proven particularly fruitful for identifying metabotropic glutamate receptor (mGlu) ligands, and there is mounting evidence that the same may hold true for muscarinic acetylcholine receptors (mAChR). 5 To date, five mAChR subtypes have been identified (M 1 -M 5 ) that play important roles in mediating the actions of acetylcholine (ACh) in the peripheral and central nervous systems. 6 Of these, M 1 and M 4 are the most heavily expressed in the central nervous system (CNS) and represent attractive therapeutic targets for cognitive illnesses such as Alzheimer's disease and schizophrenia. 7 In contrast, the adverse effects of cholinergic agents are thought to be primarily due to activation of peripheral M 2 and M 3 mAChRs. Because of the highsequence homology and conservation of the orthosteric ACh binding site among the mAChR subtypes, development of selective chemical agents for a single subtype has been largely unsuccessful. Specifically, the absence of highly selective activators of M 4 has made it impossible to test the role of selective M 4 activation. 8 On the other hand, novel compound scaffolds that behave as selective agonists, positive allosteric modulations (PAMs), or antagonists of any muscarinic receptor may have significant value as chemical probes. 9 In past literature, the term multiparametric has been used to describe assays with multiple endpoints from the same experiment. 10 Here, multiparametric is used to describe an assay in which each well provides readouts for multiple modes of pharmacology, in this case agonist, antagonism, and PAM. Multiparametric assays are an increasingly popular approach to efficiently investigate receptor pharmacology in a variety of targets; recently, these types of high-throughput screening (HTS) assays have involved mAChRs. 9 These reports, however, use different parallel processes requiring multiple compound additions to find selective, confirmed inhibitors or activators of M 4 , but not PAMs.
Here, we describe a homogenous, single-compound addition, multiparametric, 1536-well screening assay to measure M 4 receptor agonism, PAM, and antagonism in the same well. We used well-known control compounds to validate each mode; ACh for the agonist mode, ML108 for the PAM mode, and atropine for the antagonist mode. 11 The performance of this assay in an HTS campaign against a diverse, public domain compound collection is documented. Further, a methodological approach based on parallel HTS efforts is presented to better understand the behaviors of compounds demonstrating M 4 specific pharmacology in contrast to those appearing to be artifacts associated with this assay format.
Materials and Methods

Cell Lines
Human M 1 (hM 1 ) cDNA in pcDNA3.1 (+) was purchased from www.cDNA.org. hM 1 was transfected into CHO cells purchased from the ATCC (www.atcc.org), and singleneomycin-resistant clones were isolated and screened for M 1 -mediated calcium mobilization. hM 1 /CHO cells were cultured in Ham's F-12: 10% fetal bovine serum (FBS), 20 mM HEPES, 50 µg/mL G418 (Mediatech, Inc., Herndon, VA). The human M 4 (hM 4 ) cDNA in pcDNA3.1 (+) was purchased from www.cDNA.org. CHO cells purchased from the ATCC (www.atcc.org) were stably transfected with hM 4 cDNA along with the chimeric G protein G qi5 12 to facilitate measurement of receptor function via intracellular calcium in pIREShygro (Invitrogen, Carlsbad, CA) and single-hygromycin-and neomycin-resistant clones were isolated and screened for M 4mediated calcium mobilization. hM 4 /CHO-G qi5 cells were cultured in Ham's F-12: 10% FBS, 20 mM HEPES, 50 µg/ mL G418 (Mediatech, Inc.), 500 µg/mL hygromycin. Human M 5 (hM 5 ) CHO cells were a gift from the laboratory of Allan Levey (Emory University). hM 5 /CHO cells were cultured in Ham's F-12: 10% FBS, 20 mM HEPES, 50 µg/mL G418 (Mediatech, Inc.). Parental CHO-K1 cells were purchased from ATCC (Manassas, VA).
Cell Culture
Cells were cultured in T-175 cm 2 flasks (Corning, Corning, NY) at 37 °C and 95% relative humidity. Unless indicated otherwise, all cell culture reagents were sourced through Life Technologies (Carlsbad, CA). The growth media consisted of Ham's F-12 nutrient media supplemented with 10% v/v heatinactivated qualified FBS (Hyclone Laboratories Inc., Logan, UT), 20 mM HEPES, 500 µg/mL geneticin, 200 µg/mL hygromycin, and 1X penicillin and streptomycin mix. The parental CHO-K1 cell line was cultured in the same growth media lacking geneticin and hygromycin.
Fluorescent Imaging Plate Reader Assay
The assay media consisted of Ham's F-12 nutrient media supplemented with 10% v/v heat-inactivated qualified FBS and 20 mM HEPES. All assays were run in Corning 1536well clear-bottom plates (part 7338; Corning). Fluo-8 detection kits were used for all fluorescent imaging plate reader (FLIPR) assays (part 36316; AAT Bioquest, Sunnyvale, CA), which included addition of 250 mM probenicid (pH 8; Sigma, St. Louis, MO) while reading on the fluorescence imaging plate reader (FLIPR; Molecular Devices, Sunnyvale, CA). Agonist control ACh (part A6625), antagonist control atropine (part A0132), and PAM control ML108 (also known as VU0152100, part V5015) were purchased from Sigma. All additions of compound and controls were accomplished by an integrated 1536 pin tool mounted on the FLIPR Tetra. Although all three readouts occur with only one compound addition, the system does not read the well continuously but rather separates the reads by the amount of time required for the instruments' manipulation of the source plates required for the next ligand and control addition. Cell and reagent additions were performed on the Kalypsys/GNF robotic screening platform at the Scripps Research Institute Molecular Screening Center (Scripps Research Institute, Jupiter, FL). The final protocol is summarized in Table 1 . Detailed protocols for every assay mentioned in this article can be retrieved on the PubChem Web site using its respective PubChem AID shown in Table 2 .
Screening Data
Kinetic data were acquired by the FLIPR at the rate of 1 Hz. Agonist, PAM, and antagonist mode kinetic data were saved as separate data files. Individual well activity is interpreted as the ratio of the maximum signal divided by the minimum signal from the basal read or max/baseline. All data files were uploaded into the Scripps database for plate quality control (QC) and hit identification. Activity for the agonist and PAM modes was normalized on a per-plate basis using the following equation: Table 1 . M 4 ultra-high-throughput screening assay protocol in 1536-well plate format for all three modes.
Order
Step Condition Comments 
For all three modes, test well refers to those that contain test compounds. Low control wells for the agonist mode contain DMSO only. For the PAM mode, low control wells contain ACh at EC 20 . High control wells for both PAM and agonist mode contain ACh at EC 100 . Activity for the antagonist mode was normalized on a per-plate basis using the following equation:
In this case, low control is defined as wells that contain an EC 80 of ACh. High control wells contain DMSO only. A Z′ value greater than 0.5 was required for a plate to be consider valid. 13 During the primary screen, test compounds from the library were screened in singlicate at a final nominal test concentration of 3 µM (final DMSO concentration of 0.3%). For each mode, the hit cutoff used to qualify active compounds was calculated as the average percentage activity (agonist, PAM modes) or inhibition (antagonists) of all compounds tested plus three times the standard deviation. 14 Dose-response curves were fitted using a four-parameter equation describing a sigmoidal curve without constraining parameters within the Assay Explorer software (Symyx Technologies, Santa Clara, CA). Where appropriate, data have been represented using Prism version 4.03 (GraphPad Software, San Diego, CA). In those cases, EC 50 or IC 50 determinations were done using the variable slope sigmoidal curve analysis tool.
A four-way Venn diagram generator was used to compare the parental CHO-K1, M 1 , and M 5 multiparametric assay data versus the M 4 data described here. Each of these assays was run at the SRIMSC and previously published in PubChem (AIDs 588814, 588819, 588852, 624037, 624038, and 624040). The tool used is freely available at http:// www.pangloss.com/seidel/Protocols/venn4.cgi.
Screening Library
The Molecular Libraries Small Molecule Repository (MLSMR) library was provided by BioFocus DPI (South San Francisco, CA) through the National Institutes of Health's Roadmap Initiative. Details can be found online at http://mli.nih.gov/mli/compound-repository/mlsmr-com pounds/. The MLSMR library is a collection of more than 360,000 synthetic and natural small molecules from both commercial and academic sources, which can be grouped into the following four categories: (1) specialty sets of known bioactive compounds such as drugs and toxins (0.65%), (2) focused libraries aimed at specific target classes (2.85%), (3) noncommercial sources (7.4%), and (4) diversity sets covering a large area of the chemical space (89.1%).
Results
Assay Principle and Screening Strategy
As we had great interest in efficiently identifying M 4 agonists, antagonists, and PAMs for this research program, a miniaturized multiparametric FLIPR-based assay was developed. Using methods similar to those described previously but in 1536-well format, it measures receptor agonism, PAM, and antagonism from a single well, following a single addition of test compound. [15] [16] [17] [18] [19] As developed, a fully automated robotic platform accomplishes the dispensing of cells and detection reagent to the microtiter plate, as well as necessary incubation prior to the intracellular calcium assay. Intracellular calcium measurements, including test compound and control addition, are performed by the FLIPR. To enable continuous HTS, the originally separated assays were concatenated into a single assay protocol with a specific order of pharmacologic test modes: agonism was measured first, followed by PAM, then antagonism.
Each mode of detection relied on a specific set of plate controls. These controls were used either for response normalization or to verify appropriate agonist, PAM, or antagonist pharmacologic response in that mode. Figure 1 illustrates the performance of various controls in each mode of the resulting assay detection workflow that was applied to the discovery of modulators of M 4. We used three relevant controls: ACh, atropine, and ML108 as references for M 4 receptor agonism, antagonism, and PAM, respectively. Figure 1 shows examples of typical FLIPR kinetic response traces obtained for each of these reference compounds in all three modes. The first kinetic measurement, which is used for the detection of potential agonists, was initiated by the addition of test compound to cells loaded with the intracellular calcium probe. Agonists were identified as compounds that show a response three standard deviations greater than cells challenged with vehicle (DMSO). The second measurement, for detection of PAMs, was performed in the presence of EC 20 ACh stimulation. PAMs were identified as compounds in wells that exhibited a response three standard deviations greater than that of the EC 20 stimulation alone. The third and final measurement was used to detect antagonists in the presence of an EC 80 challenge of ACh. Antagonists were identified as compounds in wells that had a response three standard deviations lower than that of wells challenged with the EC 80 .
(1)
Multiparametric, 1536-Well Assay Optimization
The first step in 1536-well assay development was to optimize the cell number per well and then Fluo8 incubation time using methods previously described. 20 The signal-tobasal ratio (S/B) in the agonist mode, as calculated by the high control response divided by low control response, was not significantly affected by the number of cells plated per well. However, increasing the cell concentration resulted in suboptimal Z′ values (Suppl. Fig. 1A, B) . Hence, a cell density of 750 cells per well was chosen. Fluo8 incubation time was also optimized. The length of incubation with Fluo8 had little effect on Z′, but longer incubation times increased the S/B (Suppl. Fig. 1C) . The stability of the S/B between 60 and 90 min allows for some flexibility during robotic screening, and a 60-min incubation time was chosen for all future experiments.
Characterization of Controls
Critical to the success of the multiparametric HTS assay was the use of dedicated pharmacologic control wells specific to each measurement mode, as well as control wells that indicated the cells were competent throughout the assay (Suppl. Fig. 2) . As expected, having wells in each mode for the "high" and "low" responses facilitated the efficient identification of hits, as each well response was normalized to synchronous responses in control wells. Further, each assay mode could be treated as a unique entity in our HTS database, streamlining the plate-based QC. Unique to the multiparametric assay format, we found that additional controls, namely, an EC 0 (DMSO) in the PAM mode and an EC 100 of ACh in the antagonist mode, also aided in the efficient QC of assay quality. Specifically, we used the responses from these wells to verify the M 4 cells were fully capable of eliciting basal and full calcium responses throughout the entire assay. Kinetic traces for control compounds tested in each mode are shown in Figure 1 .
The M 4 multiparametric FLIPR assay, as outlined in Table 1 , was run in homogeneous format. All three controls as shown in Figure 1B , ACh (pEC 50 = 7.45 ± 7.65), ML108 (pEC 50 = 6.59 ± 6.91), and atropine (pIC 50 = 9.65 ± 10.22), yielded pEC 50 or pIC 50 values similar to previously published in the agonist, PAM, and antagonist modes, respectively. 11 Notably, ML108 was also found to be active in the agonist assay mode.
Data Deconvolution and Compound Triage
Successful execution of the multiparametric assay was dependent on reliable identification of hits within a mode as well as identification of a compound's pharmacologic activity across all measurement modes. For demonstration purposes, kinetic traces from a set of M 4 HTS hits are shown in Figure 2 . Within the agonist mode, a compound was defined as an agonist if it elicited a response greater than that of a vehicle (DMSO) challenge (Fig. 2, compound I) . Because the same cells are used for subsequent measurements, the magnitude of the response in the following two modes was highly dependent on the level of the response in the agonist mode. For example, an EC 100 challenge of the full agonist ACh elicits a large calcium response in the agonist mode, which persists through the PAM mode. In the antagonist mode, upon restimulation of the cells with an EC 80 of ACh, the compound fails to elicit a significant calcium response ( Fig. 1A, top panel) . This phenomenon is attributed to the depletion of intracellular calcium stores by ACh in the agonist mode, leaving less calcium available for the cells to respond to the EC 80 challenge in the antagonist mode. 21 In the case of compound I in Figure 2 , the "partial" response in the agonist mode was insufficient to deplete intracellular calcium stores, allowing for the compound to be identified as a moderate agonist hit with no PAM or antagonist activity. In contrast, compound IV behaves similarly to ACh in Figure 1A , indicating that it may be a full agonist. In this multiparametric method, an agonist that behaves similarly to ACh will be inappropriately recorded as a hit in the antagonist mode. That is, the lack of a calcium response in the antagonist mode would be similar to that of an antagonist compound and therefore incorrectly scored as a hit. This potential false-positive artifact is a strength of the multiparametric format, as it distinguished efficacious agonists (i.e., those that liberate the same calcium stores as a muscarinic receptor agonist) from partial agonists or assay artifact.
For the M 4 HTS, antagonists were defined as compounds that elicited a response less than that of the EC 80 . An example of complete antagonism is the HTS control, atropine, shown in Figure 1A . As expected, a putative antagonist would be inactive in the agonist mode and abrogate the EC 20 response in the PAM mode. Compound III in Figure 2 is an HTS antagonist mode hit that behaves similarly to atropine in all three test modes: in the agonist mode, this compound has no response; in the PAM mode, the same compound blocks the response of the EC 20 ACh challenge; in the antagonist mode, the compound completely abrogates the EC 80 response of the ACh challenge. In this case, the behavior of the hit in all three test modes of the multiparametric assay adds validity to its identification as an M 4 antagonist.
Critical to a compound's identification as a PAM hit was its behavior within the PAM mode itself; however, the identification of putative PAMs also benefitted from the multiparametric HTS approach. Ideally, a PAM would not elicit a calcium response by itself but rather in the presence of an orthosteric agonist. An example of this type of response profile is exhibited by compound II in Figure 2 , as it yields an insignificant response in the agonist mode but a significantly higher response than the ACh control EC 20 and EC 80 responses in the PAM and antagonist modes, respectively. In recombinant systems, agonist behavior of PAMs has been observed, presumably due to the overexpression of the target receptor and/or signaling mechanism components. 4, 22 This type of behavior was observed in the multiparametric HTS format for the PAM control ML108 (Figure 1A , middle panel) as well as compounds V and VII in Figure 2 ; all yielded responses in the agonist mode as well as in the PAM mode and were classified as PAMs.
Interestingly, PAM hits yielded different magnitudes of kinetic responses in the antagonist mode, appearing to have peak responses indistinguishable (cf. compound II), below (cf. compounds V,VI), or elevated (cf. compound VII) in reference to the EC 20 ACh control response. For example, compound V generated a moderate agonist and a strong PAM response, which was unable to decay to basal levels before the EC 20 and EC 80 challenges were added. However, the method for calculating the antagonist mode HTS response (i.e., the ratio of the peak response divided by the same well's baseline level response obtained just prior to the EC 80 of Ach addition) made all these compounds appear as hits in the antagonist mode. All PAM hits that displayed these patterns of responses in multiparametric HTS assay were selected for follow-up, as they could be distinguished from compounds displaying classical agonism (cf. compounds I) or antagonism (cf. compound III). However, to validate their PAM pharmacology, more detailed dose-response studies are necessary. 23 
Multiparametric Screen for the Identification of M 4 Modulators
The M 4 multiparametric FLIPR assay described above was run against the MLPCN library of 364,131 compounds. These data and the outcome of the primary counterscreen are summarized in Table 2 .
During the course of the campaign, monitoring the range of receptor stimulation and Z′ showed that, compared with basal and EC 100 controls, the PAM EC 20 response yielded an average value of 27.2% ± 1.6%, whereas the antagonist mode EC 80 response demonstrated an average value of 79.8% ± 2.2%, compared with the EC 0 (DMSO only) for an N = 302 plates. Note, a typical EC 20 response determined acceptable for screening was 10% to 30% of EC 100 , and the EC 80 response range was acceptable between 70% and 90% I.
III.
Active In : Agonist, Antagonist Selected As: Agonist The compound trace, as tested at 3 µM, in comparison to the controls for each mode is shown in blue. Red = acetylcholine at EC 100 , purple = acetylcholine at EC 80 , green = acetylcholine at EC 20 , black = DMSO only. The analysis of the traces is described in two respects: the mode/s the compound was found "active in" and then which mode the compound was progressed forward as or "selected as." of EC 100 . For this effort, the average Z′ of each mode always exceeded 0.5, as listed in Table 2 .
The results of the primary multiparametric screen yielded 503 M 4 agonist, 1450 PAM, and 2640 antagonist mode hits ( Table 2) . Each mode's hits were reanalyzed based on the hit compound's activity across the entire multiparametric assay. The results of this reanalysis method are shown in Table 2 . Of the 503 agonist hits, 281 or 55.86% were active only in that mode, whereas 97.52% or 1414 of the 1450 PAM hits acted solely in the PAM mode. Of the 2640 antagonist hits, 2389 or 90.4% had activity only in the antagonist mode. When comparing the overlap between agonist and PAM hits, only six hits acted as both an agonist and a PAM, of which five of those were also found as antagonists. All primary hits were assessed for promiscuity against the multiparametric data generated from a parental CHO-K1 cell FLIPR counterscreen ( Table 2 ) and parallel executed M 1 , M 5 HTS assays described in detail elsewhere (PubChem AIDs 588814, 588819, 588852, 624037, 624038, and 624040) and summarized below. 9, 24 
Parallel Assays for Selectivity and Promiscuity
With the goal of identifying selective M 4 modulators, we performed counterscreens against two cell lines, one expressing the M 1 receptor and the other expressing the M 5 receptor. This was done in parallel to the M 4 HTS, and each cell line was screened against the entire MLPCN compound collection. Although not described here, hit identification for the M 1 and M 5 multiparametric HTS campaigns was done similar to that illustrated in Figure 2 .
Using this approach, we found M 4 HTS hits that nonspecifically modulated the release of calcium, as evidenced by their activity in the parallel HTS assays across multiple screening modes. The method used for triaging nonspecific activators is illustrated in Figure 3 . In this example, addition of 3 µM thapsigargin, which is known to intrinsically block the ability of cells to pump calcium into the endoplasmic reticulum, results in an increase in intracellular calcium and ultimately would be identified as a hit in all modes of the M 4 multiparametric assay as well as all counterscreens run in parallel to the M 4 HTS campaign. Compounds that were inactive in the parental cell HTS campaign but active in the M 4 , M 1 , and/or M 5 HTS were similarly identified and triaged.
Venn comparison of results from the M 4 , parental, M 1 , and M 5 primary HTS assays identified M 4 HTS hits that exhibited nonspecific pharmacology or were assay artifact. Specifically, 102 agonist hits, 1318 PAM hits, and 959 antagonist hits exhibit selectivity to the M 4 receptor ( Fig.  4) . Of the 2379 combined total M 4 selective hits, in silico triage reduced the list to 2185 compounds of interest, of which 2103 were available and retested as concentrationresponse curves (CRCs) across the three modes as a 10-point, 1:3 dilution titration in triplicate. These same compounds were tested in multiparametric M 4 , M 1 , M 5 , and CHO-K1 assay formats. Following CRC assays, compounds were considered a hit only if they yielded graded dose-response curves with EC 50 or IC 50 values less than 10 µM. From these titration assays, 25 were found to be M 4 selective agonists, 4 compounds were found to be M 4 selective PAMs, and 41 compounds were found to be M 4 selective antagonists. Some of these were followed up at M 2 and M 3 when selectivity studies were performed lower in the tier, but it was not deemed that primary screening for these targets was resource and time efficient. Of the 21 compounds that progressed through M 2 and M 3 selectivity assays, only 2 were active as M 3 agonists. The individual hit cutoff applied to each of the 12 primary campaigns was low, averaging only 24.30% ± 7.68%. When combined with our method to qualify dose-response hits, this led to a small but potent and selective group of compounds being identified. In addition, similar to the triage of the primary HTS data, all CRC data were filtered to remove hits that overlapped in the other assays. Examples of the CRC data generated for the three most potent compounds for each mode of the M 4 assay are shown in Supplemental Figure 3 . These compounds are specific to the M 4 assay described here and were not found active in the others. Following this triage, there is still the potential of finding compounds that trigger a native Gi-coupled receptor in the CHO-M 4 -Gqi5 cell line and signal through the Gqi5 protein to activate calcium. Because the parental cell line does not have Gqi5, it is possible that non-M 4 receptor-mediated agonist activity could be seen in the M 4 cell line and not picked up in the CHO-parental counterscreen. We also did not include Gqi5 in the M 1 and M 5 cell lines, and hence, compounds could slip past here too. This is likely not so much an issue with PAMs or antagonists as the activity of these compounds relies on their ability to modulate ACh responses. We recognize that additional follow up of the 503 putative agonist hits will be required in an assay in which M 4 activity is monitored using a native Gi/o-dependent assay, such as M 4 coupling through potassium (GIRK) channels. 25 Similar to the M 1 -and M 5 -specific modulators described elsewhere, the details of the efficacy found for the M 4 -selective compounds including further mode of action studies, SAR (structure to activity relationship), and pharmaceutical development will be the topic for future publication. 24, 26 
Discussion
In this report, we present a homogeneous, 1536-well HTS assay that screens for a compound's agonist, PAM, and antagonist activity on the same set of cells expressing the M 4 receptor. This multiparametric assay has the benefit of reducing overall screening costs: a multiparametric HTS campaign consumes approximately one-third of reagents and cells compared with running HTS campaigns separately for each type of pharmacology. An unexpected advantage of the multiparametric format is the savings of screening campaign duration time. In our lab, an average single detection mode HTS campaign of the MLPCN collection takes 5 business days of robot time per target; in addition, scale up of cells takes an additional 10 d per screen. Here, we were able to generate three pharmacologically distinct data sets against 364,131 compounds in 8 business days of robot time with 10 d for cell preparation for a 2.5-fold reduction in time (18 vs . 45 d) .
The ability to assess a compound's behavior across the three different test modes is another advantage of the multiparametric assay format. Behavior of a hit across all three modes of the HTS assay facilitated the rapid identification of hits that were "classical" agonists, PAMs, or antagonists. The identification of agonists that exhibited more complex pharmacology was also aided by the multiparametric approach. Careful analysis of a hit's response across all modes allowed the identification of agonists that holistically desensitized the M 4 intracellular calcium response and PAMs that demonstrated agonist activity. Triage of selective hits was also aided by comparison of the M 4 primary hits with hits from three other multiparametric HTS campaigns.
Knowing that adverse effects of cholinergic agents are thought to be primarily due to activation of peripheral M 2 and M 3 mAChRs raises the question as to why we chose to triage against M 1 and M 5 . We were initially interested in M 1 , M 4 , and M 5 as targets and felt this was the most efficient way to find compounds for each target and to get an idea of selectivity. Finally, the antagonist component of the screen could potentially identify negative allosteric modulators or NAMs (negative allosteric modulators). One would anticipate these would be further elucidated in secondary assays when tested in the presence of a suboptimal concentration of a known antagonist such as atropine while looking for further diminishment of receptor signaling.
Although we successfully reduced timelines and increased output, one must be aware that assay development and implementation may take longer. Crucially, there must be pharmacological controls available for each mode in order to optimize each assay, help classify compounds, and determine their fate. Even with excellent controls, caution must be exercised. For instance, many PAM hits will not reach 100% of maximal Ach activity. Here, we set the high control as an EC 100 of Ach, which seems prudent but may have unrealistically biased us toward finding and/or normalizing data that demonstrate low activity for PAMs. In addition, data management becomes more daunting. Software tools must be put in place that allow compilation of concatenated data to yield percentage activity or inhibition for each mode. Finally, algorithms need to be established to quickly triage compounds that would qualify as agonists, PAMs, and antagonists. mAChRs play a vital role in cognitive function, making them important targets for drug discovery. Several types of modulators have been the focus of pharmaceutical companies to target mAChRs. Some of these areas include agonists, antagonists, and allosteric modulators. Efforts to develop subtype-selective, mAChR agonists have been hampered by the difficulty in achieving high selectivity for individual mAChRs important for CNS function (M 1 and M 4 ) while reducing adverse effects due to activation of peripheral mAChRs (especially M 2 and M 3 ). Major advances have now been achieved in the discovery of allosteric agonists and positive allosteric modulators of M 1 and M 4 that show greater selectivity for individual mAChR subtypes than do previous mAChR activators. Early studies indicate that these allosteric mAChR agonists and PAMs have properties needed for optimization as potential clinical candidates and have robust effects in animal models that predict efficacy in the treatment of Alzheimer's disease, schizophrenia, and related disorders. 4 To address the need for subtype-selective mAchR modulators, save time, and reduce cost, we have developed a rapid miniaturized method to detect the three aforementioned modulator types, successively, in the same well during a single assay requiring only one compound addition. Not only does this expedite the discovery of agonists, PAMs, and antagonists, but it also allows for more robust results as the variability in assay-to-assay discrepancies, day-to-day cell handling, and other environmental conditions is removed. This method has proven to be successful, as indicated by the discovery of specific probes for M 1 , M 4 , and M 5 and is the focus of follow-up research here and at other institutes. 27, 28 
